SOHM Inc Announces Key Details of Its Pharmaceutical Company Acquisition Extending Manufacturing into the US Market

SOHM, Inc., a Pharmaceutical, Nutraceutical, and Cosmeceutical firm that produces and offers generic pharmaceuticals in a variety of therapeutic areas, provided further details today about its long-awaited acquisition of a major Southern California-based pharmaceutical company.

SOHM Inc. President and CEO, Mr. Baron Night, stated, “SOHM has worked tirelessly since its inception to create and deliver transformational and urgently needed goods to patients and customers worldwide. Manufacturing under FDA licensure would strengthen our efforts and position in the cosmeceutical industry while also launching our pharmaceutical manufacturing projects, allowing us to provide more affordable solutions to more patients in need.”

SOHM now has a cGMP-compliant, FDA-licensed contract manufacturing plant that has been in operation since 2000. Through this purchase, the Company is able to initiate discussions with its distribution network for exclusive possibilities inside new verticals, resulting in an increase in revenues, profitability, and financial stability, as well as considerable value to shareholders.The acquisition facility is located in Santa Ana, California’s core, on a key traffic route. Currently, the plant manufactures semi-solid, liquid, and topical treatments and has over 300 patented formulas.

The present production capacity is 41,000 gallons per year, with the opportunity to expand to 160,000+ gallons per shift, per year inside the same facility, allowing for improved income and profitability.”We are immensely pleased with what our Company has done and look forward to the next chapter,” Mr. Night said, “and we look forward to welcoming our new partners and expanding on our combined experience in pharmaceutical production.”